Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two randomized controlled trial(s). ^[1-2]
• COMMODORE 1 (C5 Inhibitor-Experienced Patients): Crovalimab was effective in transfusion avoidance, hemolysis control, and hemoglobin stabilization, with 85% of patients preferring it over eculizumab. Improvement in fatigue levels was also noted.
• COMMODORE 2 (C5 Inhibitor-Naive Patients): Crovalimab was non-inferior to eculizumab for hemolysis control (79.3% vs. 79.0%) and transfusion avoidance (65.7% vs. 68.1%). It showed a lower incidence of breakthrough hemolysis compared to eculizumab (10.4% vs. 14.5%).
• In the COMMODORE 1 study, adverse events (AEs) occurred in 77% of crovalimab-treated patients and 67% of eculizumab-treated patients, with no AEs leading to treatment withdrawal or death. Type III hypersensitivity events were reported in 16% of crovalimab patients, were mild/moderate, and resolved without treatment modification. No meningococcal infections were reported.
• In the COMMODORE 2 study, the safety profiles of crovalimab and eculizumab were similar, with no reported meningococcal infections.
• There is no population types or subgroups information available in the reviewed studies.